Systemic inhibition of CYP24A1 can result in hypercalcemia and thus we sought to identify a CYP24A1 resistant VDR agonist, which could be given in sufficient quantities to reduce VCaP xenograft growth. Here, VDR is linked to Hypercalcemia.